Literature DB >> 19740254

Determinants of initiation and progression of idiopathic pulmonary fibrosis.

Robert Matthew Kottmann1, Christopher M Hogan, Richard P Phipps, Patricia J Sime.   

Abstract

IPF is a devastating disease with few therapeutic options. The precise aetiology of IPF remains elusive. However, our understanding of the pathologic processes involved in the initiation and progression of this disease is improving. Data on the mechanisms underlying IPF have been generated from epidemiologic investigations as well as cellular and molecular studies of human tissues. Although no perfect animal model of human IPF exists, pre-clinical animal studies have helped define pathways which are likely important in human disease. Epithelial injury, fibroblast activation and repetitive cycles of injury and abnormal repair are almost certainly key events. Factors which have been associated with initiation and/or progression of IPF include viral infections, abnormal cytokine, chemokine and growth factor production, oxidant stress, autoimmunity, inhalational of toxicants and gastro-oesophageal reflux disease. Furthermore, recent evidence identifies a role for a variety of genetic and epigenetic abnormalities ranging from mutations in surfactant protein C to abnormalities in telomere length and telomerase activity. The challenge remains to identify additional inciting agents and key dysregulated pathways that lead to disease progression so that we can develop targeted therapies to treat or prevent this serious disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19740254      PMCID: PMC3884519          DOI: 10.1111/j.1440-1843.2009.01624.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  218 in total

1.  Interferon gamma-1b for the treatment of idiopathic pulmonary fibrosis.

Authors:  T E King
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

2.  Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features.

Authors:  D S Kim; J H Park; B K Park; J S Lee; A G Nicholson; T Colby
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

3.  High-dose acetylcysteine in idiopathic pulmonary fibrosis.

Authors:  Maurits Demedts; Juergen Behr; Roland Buhl; Ulrich Costabel; Richard Dekhuijzen; Henk M Jansen; William MacNee; Michiel Thomeer; Benoit Wallaert; François Laurent; Andrew G Nicholson; Eric K Verbeken; Johny Verschakelen; Christopher D R Flower; Frédérique Capron; Stefano Petruzzelli; Paul De Vuyst; Jules M M van den Bosch; Eulogio Rodriguez-Becerra; Giuseppina Corvasce; Ida Lankhorst; Marco Sardina; Mauro Montanari
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

4.  Elevated serum and BAL cytokeratin 19 fragment in pulmonary fibrosis and acute interstitial pneumonia.

Authors:  N Dobashi; J Fujita; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Kamei; J Takahara
Journal:  Eur Respir J       Date:  1999-09       Impact factor: 16.671

5.  Survival in idiopathic pulmonary fibrosis-cytotoxic agents compared to corticosteroids.

Authors:  Carlos A C Pereira; Tatiana Malheiros; Ester M Coletta; Rimarcs G Ferreira; Adalberto S Rubin; Jaqueline S Otta; Nailê S Rocha
Journal:  Respir Med       Date:  2005-07-05       Impact factor: 3.415

Review 6.  Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts.

Authors:  M Hetzel; M Bachem; D Anders; G Trischler; M Faehling
Journal:  Lung       Date:  2005 Jul-Aug       Impact factor: 2.584

7.  Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis.

Authors:  Moises Selman; Annie Pardo; Lourdes Barrera; Andrea Estrada; Susan R Watson; Keith Wilson; Natasha Aziz; Naftali Kaminski; Albert Zlotnik
Journal:  Am J Respir Crit Care Med       Date:  2005-09-15       Impact factor: 21.405

8.  High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis.

Authors:  G Raghu; T D Freudenberger; S Yang; J R Curtis; C Spada; J Hayes; J K Sillery; C E Pope; C A Pellegrini
Journal:  Eur Respir J       Date:  2006-01       Impact factor: 16.671

9.  Idiopathic pulmonary fibrosis: how often is it really idiopathic?

Authors:  Marco G Patti; Pietro Tedesco; Jeffrey Golden; Steven Hays; Charles Hoopes; Adam Meneghetti; Tanuja Damani; Lawrence W Way
Journal:  J Gastrointest Surg       Date:  2005-11       Impact factor: 3.452

10.  TGF-beta1 induces human alveolar epithelial to mesenchymal cell transition (EMT).

Authors:  Hidenori Kasai; Jeremy T Allen; Roger M Mason; Takashi Kamimura; Zhi Zhang
Journal:  Respir Res       Date:  2005-06-09
View more
  28 in total

Review 1.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

2.  AAV1.SERCA2a Gene Therapy Reverses Pulmonary Fibrosis by Blocking the STAT3/FOXM1 Pathway and Promoting the SNON/SKI Axis.

Authors:  Malik Bisserier; Javier Milara; Yassine Abdeldjebbar; Sarah Gubara; Carly Jones; Carlos Bueno-Beti; Elena Chepurko; Erik Kohlbrenner; Michael G Katz; Sima Tarzami; Julio Cortijo; Jane Leopold; Roger J Hajjar; Yassine Sassi; Lahouaria Hadri
Journal:  Mol Ther       Date:  2019-12-06       Impact factor: 11.454

Review 3.  Signaling pathways in the epithelial origins of pulmonary fibrosis.

Authors:  William D Hardie; James S Hagood; Vrushank Dave; Anne-Karina T Perl; Jeffrey A Whitsett; Thomas R Korfhagen; Stephan Glasser
Journal:  Cell Cycle       Date:  2010-07-03       Impact factor: 4.534

4.  Transglutaminase 2 and its role in pulmonary fibrosis.

Authors:  Keith C Olsen; Ramil E Sapinoro; R M Kottmann; Ajit A Kulkarni; Siiri E Iismaa; Gail V W Johnson; Thomas H Thatcher; Richard P Phipps; Patricia J Sime
Journal:  Am J Respir Crit Care Med       Date:  2011-06-23       Impact factor: 21.405

5.  Calgranulin B (S100A9/MRP14): a key molecule in idiopathic pulmonary fibrosis?

Authors:  Elena Bargagli; Carmela Olivieri; Marcella Cintorino; Rosa M Refini; Nicola Bianchi; Antje Prasse; Paola Rottoli
Journal:  Inflammation       Date:  2011-04       Impact factor: 4.092

6.  Overexpression of Sulf2 in idiopathic pulmonary fibrosis.

Authors:  Xinping Yue; Jingning Lu; Linda Auduong; Mark D Sides; Joseph A Lasky
Journal:  Glycobiology       Date:  2013-02-14       Impact factor: 4.313

7.  Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition.

Authors:  Jason R Rock; Christina E Barkauskas; Michael J Cronce; Yan Xue; Jeffrey R Harris; Jiurong Liang; Paul W Noble; Brigid L M Hogan
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-28       Impact factor: 11.205

8.  IPF pathogenesis is dependent upon TGFβ induction of IGF-1.

Authors:  Danielle M Hernandez; Jeong-Han Kang; Malay Choudhury; Mahefatiana Andrianifahanana; Xueqian Yin; Andrew H Limper; Edward B Leof
Journal:  FASEB J       Date:  2020-02-17       Impact factor: 5.191

9.  Investigation of Toll-like receptors in the pathogenesis of fibrotic and granulomatous disorders: a bronchoalveolar lavage study.

Authors:  Giorgos A Margaritopoulos; Katerina M Antoniou; Kostas Karagiannis; Katerina D Samara; Ismini Lasithiotaki; Evi Vassalou; Rena Lymbouridou; Helen Koutala; Nikos M Siafakas
Journal:  Fibrogenesis Tissue Repair       Date:  2010-10-11

10.  Effect of lung fibrosis on glycogen content in different extrapulmonary tissues.

Authors:  Elizabeth Lage Borges; Marina de Barros Pinheiro; Luana Oliveira Prata; Wesley Araújo Sales; Yuri Augusto Junqueira Belém Silva; Marcelo Vidigal Caliari; Maria Glória Rodrigues-Machado; Maria da Glória Rodrigues-Machado
Journal:  Lung       Date:  2013-12-03       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.